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Proteomics has rapidly become an important tool for life science research, allowing the 
integrated analysis of global protein expression from a single experiment. To 
accommodate the complexity and dynamic nature of any proteome, researchers must use 
a combination of disparate protein biochemistry techniques, often a highly involved and 
time-consuming process. Whilst highly sophisticated individual technologies for each 
step in studying a proteome are available, true high-throughput proteomics that provides 
a high degree of reproducibility and sensitivity has been difficult to achieve. The 
development of high throughput proteomic platforms, encompassing all aspects of 
proteome analysis and integrated with genomics and bioinformatics technology, therefore 
represents a crucial step for the advancement of proteomics research. ProteomIQTM 
(Proteome Systems, Sydney, Australia) is the first fully integrated, start-to-finish 
proteomics platform to enter the market. Sample preparation and tracking, centralized 
data acquisition and instrument control, and direct interfacing with genomics and 
bioinformatics databases are combined into a single suite of integrated hardware and 
software tools, facilitating high reproducibility and rapid turnaround times. This review 
will highlight some features of ProteomIQ, with particular emphasis on the analysis of 
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In the wake of large scale genome sequencing projects, life science research has 
experienced a paradigm shift from the reductionist, single-protein biochemical approach 
to a more global view in the analysis of biological systems. Accordingly the field of 
proteomics, the study of the entire protein complement expressed by the genome [1], has 
experienced explosive growth and has become a revolutionary tool with promising 
applications across the biological sciences. Proteomics involves the systematic study of 
the identity, distribution, abundance and modifications of large sets of proteins from 
biological samples such as cells, tissues or fluids. Proteins are typically extracted, 
separated and analyzed using a diverse array of protein biochemistry technologies. By 
comparing the proteome of samples derived from normal and disease states or from 
differing metabolic conditions, for example, phenotypic or functional changes can be 
correlated with their underlying biochemical or pathological events. A major advantage 
of this global approach is that many changes can be considered in an integrated manner 
from a single experiment. Not surprisingly, there has been intense interest in the 
application of proteomics to foster better understanding of disease, identify new 
biomarkers to improve diagnosis, detection and prognosis, and to accelerate the 
development of new and existing therapeutics [2-5]. 
The proteome of any organism is highly variable and dynamic in nature, since 
protein expression and modification respond to both internal and external stimuli and are 
dependent on cell type, growth conditions, environmental influences or disease status. 
The analysis of an individual’s proteome therefore generates large amounts of 
information, leading to the requirement for a highly coordinated approach to data 
collection, storage and analysis. Initiatives such as the Human Proteome Organization’s 
(HUPO) Proteomics Standards Initiative (PSI) (http://psidev.sourceforge.net/) and the 
Seattle Proteome Center’s Institute for Systems Biology (ISB) 
(http://www.proteomecenter.org/) are good examples of the effort to “develop, apply and 
disseminate” new technologies aimed at standardization of the approaches used to 
generate proteomic data. The often high throughput nature of proteomic studies and the 
large datasets generated from such analyses also requires that rigorous comparison across 
statistically significant numbers of samples can be performed with a high degree of 
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reproducibility and sensitivity. Automation of as many operations as possible during the 
generation of a proteome can minimize variability and significantly enhance the 
consistency and reproducibility of the data generated. Companies such as Amersham 
Biosciences [101] and BioRad [102] now market purpose-built, automated proteomics 
equipment for processes such as IEF, gel electrophoresis or spot cutting. 
Despite technological advances, equipment for proteomic analyses is typically 
stand-alone and lacks integration- a situation which can contribute significantly to the 
complexity of results and bottlenecks in downstream analysis. The development of high 
throughput proteomics technology platforms, encompassing all aspects of proteome 
analysis and integrated with genomics and bioinformatics technology, represents a crucial 
direction for the advancement of proteomics research. The major challenge for any 
proteomics platform is to establish technologies which provide reliable, efficient and 
reproducible data acquisition and analysis procedures that are amenable to high 
throughput. ProteomIQTM (Proteome Systems, Sydney, Australia) [103] is a suite of 
proteomics technologies comprising instruments, consumables and software, integrated 
through an information management and analysis system, and was the first fully 
integrated proteomics platform to enter the market [6]. Since two-dimensional 
polyacrylamide gel electrophoresis (2DE) remains the most commonly used technology 
for proteomics, we will focus on the use of ProteomIQ in the generation of proteomic 
data from 2DE arrays. 
 
Dealing with the diversity of the proteome 
The highly variable and dynamic nature of protein expression and modification 
presents a number of unique challenges to the proteomics researcher, since any particular 
organism will have many permutations of its proteome dependent on cell type, growth 
conditions, environmental influences or disease status- all of which may influence the 
protein expression profile of a cell at any particular time. Whilst knowledge of the 
complete genomic content of humans and a number of pathogenic and biologically 
relevant organisms has become part of an indispensable platform for mining proteomic 
data, the DNA expression profile of a static genome does not reflect the additional 
dynamics of transcriptional and translational controls, and post-translational 
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modifications of proteins. For example, sequencing of the human genome has revealed 
between 20000 to 25000 protein-coding genes[7, 8], not significantly different to the 
25498 protein-coding genes found in organisms such as Arabidopsis thaliana [9]. The 
additional complexity of the proteome can arise through splice and translation isoforms, 
and post-translational processing and modifications such as glycosylation, 
phosphorylation or acetylation [10-13]– in some cases, up to 1000 potential species of a 
single protein, based on transcriptional isoforms, have been described [14]. Taking such 
modifications into account, the estimated total number of protein species will therefore be 
orders of magnitude higher than the number of genes observed in any individual genome 
[15].The occurrence and significance of such modifications, induced by intra- or extra-
cellular stimuli or environmental responses, all contribute to the biological role of 
proteins in vivo and can neither be predicted nor understood from the genome. Proteins 
also display a wide dynamic range of expression levels; for example, 5-6 orders of 
magnitude in yeast [16], and by at least 12 orders of magnitude in human blood serum 
[17, 18]. Every sample therefore has the potential to produce large numbers of complex 
proteomic permutations, characteristic of specific cell types, growth conditions or disease 
states. 
To accommodate the complexity of the expressed proteome, a typical 2DE 
proteomics workflow encompasses a number of sequential steps (fig 1). The first of these 
involves the isolation of proteins from a sample using a suitable cocktail of detergents 
and denaturants. This must be done under conditions which are amenable to subsequent 
manipulations in the proteomics process. In even the simplest proteome, proteins often 
differ in abundance, size, pI and solubility, and thus sample fractionation prior to further 
analysis is often undertaken at this point to reduce sample complexity. Next, the isolated 
proteins are separated (generally in triplicate) by 2DE and the gels typically Coomassie 
blue, silver or SyproRubyTM (Molecular Probes) [104] stained. Image acquisition and 
analysis of the stained polyacrylamide gels is performed to identify differences in the 
profile of expressed proteins, and those identified as potentially interesting are flagged 
for further analysis. These proteins are then excised from the polyacrylamide gel, 
enzymatically digested and the purified peptides submitted for MS analysis. The identity 
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of the protein/s analyzed may then be determined by peptide mass fingerprinting (PMF) 
or peptide fragmentation fingerprinting (PFF).  
 
Sample preparation and pre-fractionation 
Of primary importance in any proteomic investigation is the preparation of 
samples in an appropriate format for presentation to 2DE. The protein composition of any 
sample can be extremely varied- relative protein abundances, charge, size, pI or 
solubility, for example- and successful preparation requires an intimate knowledge of the 
sample and a clearly defined strategy to target proteins of interest. Typically, a sample is 
collected and often subjected to an “enrichment” stage prior to protein isolation- for 
example, the sub-cellular isolation of organelles or plasma membranes, or membrane 
stripping protocols designed to remove peripheral proteins [19]. Care must be taken to 
ensure consistency during the collection and enrichment phase, prior to entering the 
proteomics factory, as elements such as sample collection methods or storage may affect 
the quality and protein composition of the sample [20]. Proteins are then solubilized, 
denatured, reduced and alkylated in an appropriate cocktail of nonionic or zwitterionic 
surfactants, chaotropes and salts that are compatible with first dimension isoelectric 
focusing (IEF) [21]. The composition of the cocktail depends on the proteins being 
targeted- for example, membrane or cytoplasmic proteins- and no one solution is ideal for 
all samples [21]. Standardized methodologies for particular sample types are, therefore, 
extremely important to ensure reproducibility and consistency when preparing samples 
for 2DE. A number of commercial kits, specifically tailored to particular sample types 
and protein sub-classes, are available for optimized sample preparation. Companies 
including BioRad [102] (ReadyPrepTM), Pierce [105] and Sigma [106] all market kits for 
protein isolation and fractionation. Consumables in the ProteomIQ platform (table 1) 
include extraction kits for the preparation of general or membrane proteins, and also for 
the depletion of albumin from serum and plasma. 
Pre-fractionation prior to IEF is an important part of sample preparation, reducing 
sample complexity and increasing the protein load which may be separated on narrow-pH 
gradient gels by IEF [22]. This theoretically allows increased resolution, enrichment of 
low abundance proteins, specific targeting of proteins with particular pI values or 
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elimination of proteins from a sample (e.g. serum albumin, which accounts for ~60% of 
protein present in human plasma) and also allows tailoring of isoelectric fractions to 
specifically match narrow range IEF strips [23]. A number of preparative pre-
fractionation devices, their uses and limitations have been recently reviewed [23, 24]. 
ProteomIQ includes a multi-compartment electrolyzer (MCE) which fractionates proteins 
according to their isoelectric points (fig 2a). A series of liquid-filled chambers are 
separated by semi-permeable membranes, each of which carries an immobilon-containing 
gel of a particular pH value [22]. When a potential difference is applied across the MCE, 
a discontinuous pI gradient is established where the pI of each membrane delimits the pI 
range of proteins focusing between them- in effect, a series of isoelectric “traps”. 
Generally, three fractions are produced (alkaline, neutral and acidic) although any 
combination of membranes may be used. This allows targeting of particular sub-
proteomic fractions such as alkaline proteins, which are often under-represented in 
proteomic analyses, and the efficacy of isoelectric prefractionation in 2DE studies has 
been demonstrated for proteins from Escherichia coli and human plasma [22], and also 
for low abundance and membrane proteins from the yeast Saccharomyces cerevisiae [25]. 
A similar strategy is employed by the BioRad Rotofor [102], which relies on the use of 
ampholytes rather than membranes during the isoelectric fractionation. This approach has 
the significant advantage that protein losses due to precipitation onto the isoelectric 
membranes do not occur. Unlike Rotofor, ProteomIQ’s MCE is modular and designed 
specifically for use in a bench-top electrophoresis device (IsoelectrIQ or ElectrophoretIQ- 
see below), requiring no external power supply or vacuum. Using MCE to fractionate 
samples prior to IEF, the authors have had great success in displaying proteins from 
traditionally “difficult” samples [26, 27] such as the alkaline pH 6.5-11.0 fraction of the 
gram positive bacterium Bacillus subtilis  (fig 2b).  
  
Protein Separation and Image Analysis 
The most commonly used technique for protein separation remains 2DE, probably 
because of its economy, accessibility to most laboratories and a wealth of previous 
experience to draw upon [5]. In the first dimension, proteins are focused in an IPG strip. 
Commercially available pre-cast IPG’s are highly reliable and offer a wide range of broad 
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or narrow pH gradients. Several companies market pre-cast IPG’s and focusing hardware. 
Amersham Biosciences [101] and BioRad [102] market the Ettan IPGphor and Protean 
IEF Cell, respectively, whilst ProteomIQ uses the IsoelectrIQ (fig 3a). In each case, the 
instruments are equipped with cooled platforms, on-board protocols and variable voltage, 
current and temperature parameters. IsoelectrIQ has greater throughput (up to 36 IEF 
strips focused at once, via 3 independent power supplies, versus 12 or 24 respectively) 
and also offers preparative pre-fractionation via MCE. 
Following IEF the proteins are separated in the second dimension by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Second dimension 
polyacrylamide gels, when combined with first dimension IEF, still offer a number of 
advantages over non-gel systems in that they are able to separate, to homogeneity, 
hundreds or even thousands of proteins in a single step, can resolve intact protein 
isoforms, and are not overtly biased against any particular type of proteins (although, 
specialized gels and buffer systems might be required to deal with particular classes of 
proteins- e.g. acidic, basic, or hydrophobic proteins) [5, 28]. Resolution can also be 
varied according to the size of the gel, and so-called “zoom” gels, where IEF is 
performed in narrow pH range IPG’s, may be used to achieve higher proteins loads in 
discrete pH ranges [5]. The major requirement for this step is that the polyacrylamide 
gels are prepared with a high level of consistency. Pre-cast polyacrylamide gels that give 
highly reproducible results are now available (e.g. Biorad [102], Gradipore [107]). 
BioRad’s Mini PROTEAN minigels can be completed in around 40 minutes, whilst the 
large format (26x20cm) gels used in the Ettan DALT gel system take around 6 hours. 
ProteomIQ uses a pre-cast, tris-acetate GelChipTM mini-gel format (10x15cm) designed 
for use in the ElectrophoretIQTM (fig 3b), with run times typically around 90 minutes for 
8 gels. ElectrophoretIQ also is able to perform isoelectric focusing, MCE or Western 
blotting; as for IsoelectrIQ, any combination of equipment modules (fig 3c) may be run 
simultaneously from the separately controlled power supplies. 
After separation of proteins by 2DE, the polyacrylamide gel is typically stained 
(although alternate labeling technologies, such as isotopic or fluorescent labeling, may be 
used- see [29] for a recent review) and in silico image analysis performed to identify 
differences in the pattern of protein expression. Image analysis remains as a bottleneck in 
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most proteomic analyses, and no single package has the capacity to perform image 
analysis without user intervention [13]. ProteomIQ uses an AlphaImager™ 3300 (Alpha 
Innotech) [108], to capture 12-bit images to a resolution of 40 microns using a cooled 
CCD camera; however, any generic image capture platform may be used- (for example, 
the BioRad VersaDoc 4000 has similar capabilities). High resolution images can also be 
captured using laser-based scanners such as the Amersham Typhoon [101]. These are 
particularly useful if double fluorescent staining, such as with the Cy-3 and Cy-3 dyes, 
are employed.  
Following image capture, image analysis software performs spot detection, gel 
matching, spot quantitation and reporting for images derived from the scanned sets of 
gels. Numerous programs including PDQuest (BioRad) [102], Ettan LWS (Amersham 
Biosciences) [101], Melanie (GeneBio; also named ImageMaster 2D Platinum, from 
Amersham Biosciences and GeneBio) [109], Proteomweaver (Definiens) [110] or 
Progenesis (Nonlinear Dynamics) [111] are available for this. ProteomIQ interfaces 
directly, via application program interface (API), with either Progenesis [111] or 
ImagepIQ™, an image analysis program developed in-house which performs analyses on 
all 2DE gels except those using DIGE [101] technology. First, filters are applied to 
parameters such as background subtraction and spot detection thresholds and spots are 
detected in the scanned image. Anchor points for gel matching are chosen manually, and 
a composite virtual gel with normalized spot volumes is created from the replicate image 
sets. The ImagepIQ program includes vectoring and color overlays for observation of 
differentially expressed spots, and matching of composites can be performed in the same 
manner. Reporting includes integrated statistical analyses for each match.   The 
performance of some of these image analysis packages have been recently compared and 
contrasted in two publications [30, 31].  
 
Protein digestion and peptide analysis 
Spot cutting, washing and digestion of protein spots from gels can be demanding, 
and are often a major bottleneck in proteomic investigations. Using robotic platforms for 
spot excision from gels and subsequent liquid delivery steps minimizes handling and 
avoids contamination or the introduction of inconsistencies. Typically, these platforms 
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consist of an image capture platform linked to spot cutting and liquid delivery systems. 
The major requirement here is for precise spot cutting to minimize contamination, along 
with complete automation and rapid turnaround times to facilitate high throughput. 
Several companies produce commercially available benchtop equipment covering one or 
more of the spot cutting, liquid delivery and MALDI target deposition processes. The 
ProteomeWorks Spot Cutter [102] cuts 200 spots/hour, using a digital image captured by 
an on-board 12-bit camera and illumination source (UV or visible light). Amersham 
Biosciences [106] markets the Ettan Spot Picker, Digester and Spotter, a series of 
instruments which excise protein spots from gels and follow an automated procedure 
from destaining through to deposition of samples onto a MALDI target plate. Markers on 
the gel backing are used to align the gel on the Spot Picker in accordance with a digital 
image (“blind cutting”), and spots are cut (96 spots/30 mins) and deposited into microtitre 
plate wells. These plates are transferred manually to the digester, where the gel plugs are 
washed, dried and digested. On completion of digestion, the plates are manually 
transferred to the Spotter and deposited to a MALDI target plate (384 spots/3 hours) for 
further analysis. At each step, “plug and play” routines are used to track the samples 
between spot cutting and deposition on the MALDI target. 
ProteomIQ includes the completely automated Xcise robotic cutting platform (fig 
4), for these processes. Images are acquired using an on-board 300dpi, 24 bit color 
flatbed scanner. Typically gels are Coomassie or silver-stained prior to scanning, 
although blind cutting may be performed in a manner similar to that used by the Ettan 
Spot Cutter (in which case, image acquisition at this stage is not required). Spot cutting 
(150 spots/hour), liquid delivery and protein digestion, and MALDI target deposition are 
performed with similar efficiency to the Amersham Biosciences instruments and similar 
sample tracking facilities. A major advantage of the Xcise, however, is that it is a single, 
enclosed, bench top instrument and no user intervention is required- this not only saves 
lab space and decreases throughput time, but also eliminates any potential problems 
which might arise during manual sample transfer between robotic instruments. 
An interesting inclusion in the ProteomIQ platform is the ChIPTM (Chemical 
Inkjet Printer- fig 5a), the result of collaboration between Proteome Systems [103], 
Shimadzu Biotech [112] and MicroFab Technologies [113]. This instrument is designed 
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to process samples that have been transferred onto a PVDF membrane, essentially 
forming a protein array for each experiment. ChIP works on the principle that a 2DE gel, 
blotted onto a membrane, represents a unique protein macroarray [32]. Unlike protein 
microarrays, which are constructed from a finite set of known proteins [33], such a 
macroarray theoretically includes both known and unknown protein isoforms complete 
with co- and post-translational modifications. Protein analysis using the ChIP begins with 
immobilization of proteins onto a PVDF membrane (i.e. conventional blotting). 
Following image capture and selection of protein bands of interest, a piezoelectric 
microdispensing system is used to print nanolitre volumes of reagents (drop size 55μm) 
onto the membrane’s surface (fig 5b and c). Dispensing is non-contact, allowing multiple 
dispensations onto a single protein spot without contamination. By dispensing minute 
amounts of primary and secondary antibodies, blocking solution and developing reagents 
precisely onto the protein band of interest (fig 5c), the ChIP has successfully been used to 
perform “nanoWestern” blotting. This strategy allows detection of multiple antigens from 
a single blot (fig 5d) or multiple chemistries to be dispensed onto a single protein spot. 
Dispensing reagents for MS analysis has also been achieved, allowing identification of 
proteins by MALDI-TOF directly from the membrane [32]. 
This approach offers some significant advantages. By bringing the chemistry to 
the protein, multiple liquid handling steps where protein can be lost are bypassed. The 
use of reagents such as antibodies, antigen, enzyme, MALDI matrix or membrane is also 
significantly reduced, resulting in lower costs for 2DE investigations. The reduced 
requirement for reagents is also important where samples are difficult to obtain or are in 
very limited supply (for example, clinical isolates). Using the ChIP, the detection of 
proteins by peptide mass fingerprinting (PMF) has been demonstrated in the 5-15 fmol 
range, and sensitivity of western blotting is comparable to conventional methods [32]. 
Second, liquid is dispensed onto only a portion of the protein spot to be analyzed, 
allowing multiple chemistries (and thus multiple experiments) to be performed on a 
single spot. This might include the use of multiple enzymes prior to MALDI-TOF 
analysis to increase peptide coverage by PMF, dispensation of multiple chemistries to 
examine protein activity or composition, or detection of multiple proteins from a single 
lane by western blotting. Also, because the proteins embedded on the PVDF membrane 
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are derived from a real sample, post-translational modifications can be characterized as 
has been demonstrated for the glycosylation of human plasma proteins [32]. Third, the 
PVDF membrane may be stored, allowing further testing of proteins from an experiment 
when new protocols or chemistries become available, new targets are identified or new 
ideas occur. The potential use of this technology as a diagnostic tool has already been 
demonstrated [32], and the ChIP promises to become an extremely important adjunct to 
current proteomics applications.  
 
Protein Identification, Informatics and Validation 
The final step in the 2DE proteomic workflow is the identification of protein spots 
by MS analysis. Whilst a number of different types of MS procedures are now available 
[34, 35], MALDI-TOF and ESI-TOF remain the two most commonly employed. 
MALDI-TOF is particularly well suited to proteomic analyses, as it is easily automatable 
and so is amenable to high throughput. It also has the advantages of high sensitivity and 
excellent resolution, and therefore is most commonly employed in high throughput 
proteomic analyses for protein identification [12]. The combination of MALDI-TOF and 
2DE also offers some advantages over non-gel based proteomics approaches. Typically, 
LC-MS systems separate peptides in complex mixtures, providing identification of many 
more proteins than is possible from a 2DE system. However, identification is typically 
based on only one or a few peptides, and the intact protein is never observed [28]. This 
prevents additional protein coverage and makes identification of protein isoforms 
difficult [28]. The combination of MALDI-TOF and 2DE allows identification of tryptic 
peptides derived from the entire isolated protein, typically providing good coverage.  
Since the intact protein is the starting material it is possible to examine individual 
modifications on peptides, providing information on the biological function and status of 
the protein [28]. ProteomIQ is marketed with the Axima-CFRTM Plus MALDI-TOF MS 
from Shimadzu Biotech [112], which is capable of automated spectra acquisition and 
provides resolution at 60ppm. The Axima MALDI-TOF MS also performs post source 
decay (PSD), which can provide sequence information from peptides and increase the 
confidence of identifications obtained by PMF. ProteomIQ also supports and integrates 
mass spectrometers from other vendors, and a generic mass spectrometer interface 
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included in the platform allows information from other instruments, such as the Bruker 
Autoflex (Bruker) [114] or the Micromass Q-TOF (Waters Corporation) [115], to be 
captured and stored as part of a proteomics experiment. 
Following collection of MS data the spectra must be processed and compared to 
theoretical peptide masses, generated from a genomic or protein database, in order to 
identify the gene encoding the isolated protein. ProteomIQ contains tools for the 
processing and analysis of MALDI-TOF MS data, as well as post-source decay (PSD) 
and tandem mass spectrometry (MS/MS), and includes all bridging software and 
algorithms necessary for peptides and protein identification. Monoisotopic mass spectra 
peaks are harvested automatically using the Peak Harvester tool, which first processes 
spectra and then applies Poisson modeling to determine which peak in an isotopically 
resolved group represents the monoisotopic peptide mass [36].  Following peak 
harvesting, reliable protein identification can depend on several factors including the 
quality of MS data produced, the number of masses or mass distribution of masses 
submitted for query- the key problem in identification remains that peptide masses are 
generally not unique, and random matching of a peptide to a database sequence may 
produce a false positive [37]. In ProteomIQ, the harvested peptide masses are submitted 
to the IonIQ search engine, which uses a modified MOWSE scoring system [38] to assign 
a measure of probability to protein identifications, for PMF. Queries are submitted to 
SWISS PROT, TrEMBL (Swiss-Prot, TrEMBL, and PIR database information is now 
contained in UniProt; http://www.ebi.uniprot.org) or proprietary databases, and potential 
protein identifications and probability scores are returned along with links to the 
annotated gel(s) and integrated MS data viewers. Where peptide identification is 
ambiguous, further peptide fragmentation by PSD or MS/MS may be undertaken and 
ProteomIQ also includes search engines for analysis of these data types. Comparisons 
between several different scoring algorithms, including MS-FIT and MASCOT (which 
use a MOWSE scoring system), ProFound and SEQUEST have been recently reviewed 
[37]. A significant improvement in the pipeline would be the integration of several search 
engines to be used simultaneously for automated protein identification from MS data; 
thus far, algorithms implementing this kind of search are unavailable. 
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Protein identification by MS analysis ultimately requires experimental validation, 
especially where proteins match the database records for “hypothetical proteins” or 
“putative function”. The nature of the validation process depends greatly on the kind of 
study undertaken, and the transition from putative protein identifications to specific 
biological or functional analyses is a limitation for many studies.  The LIMS component 
of BioinformatIQ accommodates a number of sample preparation, electrophoretic or 
other handling procedures and allows uploading and association of third party data with 
any particular experiment. In this way, all subsequent validation information for the study 
may be stored in the central database. 
 
Data Management, Integration and Quality Control 
The major challenge facing proteomics resides in integration of the complex 
processes and management of the diverse data types generated during analysis of a 
proteome. The Scierra™ Proteomics LWS and Ettan Spot Handling System [101], the 
ProteomeWorks™ System [102], ProteomIQ [103] and the Bruker ProteinScape [114] 
are platforms which integrate the processes of 2D gel generation, image analysis and 
protein identification. In any project of a size sufficient to require automation, tasks such 
as sample tracking, linking samples to gels, or linking protein spots to database entries 
rapidly become overwhelming and software tools to manage these processes are of 
paramount importance. BioinformatIQTM is the web-based software platform that fully 
integrates and manages all hardware, data acquisition and analysis in ProteomIQ. The 
software is hosted on a scalable 64-bit IBM pSeries server or on Linux-based Intel 
servers, and functions both as a centralized laboratory information management system 
(LIMS) and a suite of data analysis modules. The LIMS component of BioinformatIQ is 
an IBM DB2 relational database, with a web-based interface accessible from any desktop 
PC connected to the network or across the internet. It enables remote monitoring and 
external control over experiments and allows all information concerning sample 
management, experimental methods and results to be captured and stored in the 
centralized database. The LIMS is scalable according to need, and accommodates both 
standard and customized experimental workflows for both 2DE and non-gel proteomics 
but does not have a worksheet generation capacity. Data capture from all hardware in 
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ProteomIQ is automatic; the system also supports data import from third party 
instruments (e.g. plate readers), but does not manage the hardware in this case. The 
Amersham Biosciences platform also provides limited third party support. A commercial 
platform allowing integration of either an alternate provider’s or home-built tools, and 
data sharing in a common format, would be particularly advantageous, but none of the 
currently available platforms accommodate this degree of flexibility yet. 
Large amounts of data are generated from even a simple proteomic workflow, and 
thus data management is of paramount importance. The Ettan LWS [101], ProteinScape 
[114] and BioinformatIQ offer complete sample tracking, from initial sample acquisition, 
through the protein separation process to ultimate data mining and linking of individual 
spots on a gel with protein identification. In each case, bar-coding or transponder-based 
technology is initially used to assign unique sample identities and to manage and track 
sample fate. Information concerning each sample, including the biological source, 
method of isolation, transport, storage and so-on may be entered into a database (an 
Oracle™ database in the case of Ettan LWS). Unique identification of samples in this 
manner greatly simplifies the management of complex processes and reduces the 
potential for downstream confusion of samples. In BioinformatIQ, the user enters 
experimental procedures as they are performed (using either pre-defined or customized 
methods); the workflow for each individual experiment is stored in the database and 
displayed as a hierarchical tree, with links to each procedure and the associated data 
collected (fig 6a and b). In this way, BioinformatIQ also functions as an electronic lab 
book that allows real-time data acquisition and accurate, rapid sharing of methods and 
data across a network or secure web connection. Multiple and complex queries can be 
processed by the LIMS, and various report types for all stages of the workflow generated.  
Integration between hardware and software is a key requirement for any 
automated proteomics platform, facilitating accurate data capture and analysis and 
avoiding bottlenecks. A unique feature of BioinformatIQ is direct interfacing with all 
instruments in the platform: all hardware components of ProteomIQ provide run 
information directly to BioinformatIQ, and this is automatically uploaded into the central 
database and associated with the appropriate experiment. This information may also be 
used to generate the next step in the proteomic workflow. For example, following image 
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analysis by ImagepIQ protein spots of interest can automatically be uploaded to Xcise for 
spot cutting. BioinformatIQ and Xcise also interface with Progenesis [111] via defined 
file formats; information from other image analysis packages may also be uploaded and 
stored, but is not integrated to the same degree. Liquid handling data generated by Xcise 
is automatically uploaded into BioinformatIQ, which then generates positional 
information correlating each protein spot processed with the subsequent position of 
eluted peptide on a MALDI target plate. This information then drives automated 
acquisition of PMF data- the only user intervention required throughout these processes is 
the manual transfer of the MALDI target plate from Xcise to the MALDI-TOF 
instrument.  
The generation of large amounts of data requires careful quality control, and the 
issues of technical and biological variation in quantitative protein expression profiling 
were recently assessed [39]. Many sources of variation in quantitative 2DE analyses are 
possible- for example, biological variation in protein levels between experiments, error 
introduced during sample preparation, protein staining/labeling or gel running, or 
quantitation errors during image analysis and background subtraction [40]. Information 
capture is therefore of paramount importance to address the statistical aspects of variance 
in an experiment [40]. In the ProteomIQ platform, information concerning all aspects of 
the 2DE process- from sample preparation, through 2DE separation conditions and 
ultimately to MS analysis- is captured and stored in the LIMS. Integrated platforms such 
as ProteomIQ, ProteinScape or Ettan LWS also limit procedural inconsistencies by 
minimizing user intervention. Whilst no instrument is faultless, centralized data 
acquisition, storage and automated analyses facilitated by the software package 
controlling the platform all contribute to maintaining the quality of data output.  
 
Non-gel based proteomics 
Whilst this review is focused on the generation of 2DE arrays, each of the 
BioRad, Amersham Biosciences and Proteome Systems platforms also includes an 
automated LC-MS/MS platform for the separation and resolution of peptides in complex 
mixtures. This is useful for large-scale analyses of proteins present in the proteome, 
which exist in at least one form at any particular time. Automated LC-MS systems have 
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been widely used in “shotgun” approaches to proteomics (for review, see [12]), generally 
presenting peptides for ESI-MS/MS analysis. ProteomIQ uses a LCQ™ Deca XP Plus 
[116] with an on-board LC system, and is integrated with ProteomIQ via BioinformatIQ. 
The use of LC-MS/MS can enhance the ability to resolve protein modifications, or 
provide additional protein coverage and thus more accurate protein identification and 
analysis of post-translational modifications. Non-gel based proteomics therefore forms an 
important complement to any high-throughput 2DE platform. 
 
Conclusion 
Proteomics has emerged as a powerful tool for the global analysis of biological 
systems, and has clear potential for accelerating the discovery and development of new 
diagnostic and therapeutic molecules [2-5]. ProteomIQ is the first high-throughput, 
purpose-designed proteomics platform that successfully integrates existing and emerging 
proteomics technologies. Several studies have already demonstrated the versatility and 
efficacy of ProteomIQ for integrated proteomic analyses. These include the identification 
of low abundance and membrane proteins from the yeast S. cerevisiae [25], identification 
of novel biomarkers from sputum and serum samples of patients suffering from cystic 
fibrosis or tuberculosis, and the identification of protein glycosylation modifications on 
mucins isolated from the sputum of CF patients, which have potential as novel diagnostic 
or therapeutic molecules [41]. The application of multiple chemistries to single protein 
spots using the ChIP has also been established, and has enormous potential for high-
throughput proteomics and development of new diagnostic approaches [32]. The authors 
are currently using ProteomIQ in a proteomic analysis of the cell cycle in bacteria, aimed 
at identification of novel antibiotic targets and new therapeutic agents. 
The development of high throughput platforms that are purpose-designed 
represents a major advancement in proteomics technology. Integrated proteomics 
platforms will become more common- Amersham Biosciences [101] and ThermoElectron 
Corporation [116] have recently launched a similar integrated platform (Ettan Spot 
Handling Workstation and Scierra™ 2D-MS LWS software) and BioRad [102] market 
the ProteomeWorks™ System [6]. These platforms offer high-throughput screening 
integrated with the genomics and bioinformatics capabilities necessary for identification 
 19 
of biomarkers, drug targets and drug leads. Large lists of proteomic profiles for 
cataloguing are of limited value, and more targeted experimental approaches merging 
systems biology and hypothesis-driven research will become routine. The ability to 
perform iterative, efficient systematic profiling of differentially perturbed systems is vital 
for advancing proteomics research. 
 
Expert Opinion and Five Year View 
Several key areas are expected to develop proteomics research further in the 
immediate future. These include improved detection systems for 2DE based proteomics, 
increased use of non-gel based proteomics, and further developments in informatics for 
handling and analyzing the huge datasets generated by proteomics researchers. 
 2DE remains the most commonly employed technique for proteomics, but as yet 
it has proven to be limited particularly for the display of low abundance and membrane 
proteins [42, 43]. These classes of proteins require specialized protocols and preparation 
methods, based on their particular compositions. We have recently had success in 
isolating and displaying membrane proteins from the gram positive bacterium B. subtilis, 
based around development of new sample buffer compositions and sample treatment 
protocols (A.N. Stephens, S.K. Pedersen, E.J. Harry, unpublished results). Whilst sample 
preparation methods continue to make incremental improvements in protein solubility, 
new detection systems which are compatible with current 2DE separation and detection 
technologies will provide enhanced resolution of the proteome and still be economically 
attainable for most researchers. Advances have been made in protein labeling 
technologies, including fluorescent dyes, chemical reagents and radioisotopes (for 
review, see [29]). For example, multi-labeling techniques can significantly reduce the 
time taken for image analysis of 2DE arrays, and also reduce the number of gels which 
must be produced. Affinity purification using anti-phosphoprotein antibodies and 
immobilized metal ion affinity chromatography has been used extensively for 
phosphoprotein enrichment (reviewed in [24]). New strategies for the chemical 
derivitisation of phosphate groups on serine or threonine residues to incorporate a thiol 
group [44] or biotin tag [45] as an affinity handle have also been reported, as has a new 
fluorescent reagent (Pro-Q Diamond phosphoprotein dye [104]) specific for 
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phosphoproteins and suitable for their detection after separation by 2DE [46, 47]. 
Enhanced detection of proteins using existing instrumentation would be an enormous 
asset to researchers, enabling deeper proteomic analyses without the cost associated with 
the purchase of more sensitive equipment. Quantitative protein detection, whether via 
labeling technology or quantitative MS techniques, could eliminate the need for a 
reference gel and represents a major potential advancement for future proteomics 
research. 
 Apart from new labeling technologies, increased sensitivity of MS 
instrumentation will also be important in providing a greater depth of proteome 
characterization. Accelerator MS, where atoms are accelerated through a high voltage 
field to strip away outer valency electrons and the resulting positive species analyzed 
[48], can provide protein sequence information at the attomole level [35] and would 
potentially be extremely useful for low abundance proteins. Of course, complementary 
sensitivity in detection and a capacity to process low abundance proteins without high 
losses will be essential for increased MS sensitivity to be effectively employed. In 
addition, current MS techniques are still not adequate for the analysis of complex post-
translational modifications, although much progress has been made [35].  
Non-gel systems are gaining popularity and show great promise in the separation 
and global analysis of proteins [12, 20]. Techniques such as multi-dimensional protein 
identification technology (MudPIT), where peptides are separated based on their charge 
and hydrophobicity prior to submission for ESI-MS/MS, theoretically allows large 
numbers of proteins to be identified [3]. Isotope-coded affinity tagging (ICAT) [49] 
allows quantitative expression profiling in an LC-MS/MS system by using isotopically 
coded tags to specifically label proteins. A number of other labeling chemistries have also 
been explored (reviewed in [12]). Whilst LC-MS/MS remains slow compared to MALDI-
TOF MS [50] it is easily automated and recent work has demonstrated the comprehensive 
analysis of both soluble and membrane proteins [51, 52]. Non-gel proteomic systems will 
therefore provide an important complement to 2DE in the future. 
Protein microarrays have begun to appear and have enormous potential as an 
adjunct to 2DE as protein identification, quantitation and interaction analysis tools [53]. 
Protein arrays are typically constructed from a known subset of proteins, such as 
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antibodies or recombinantly expressed proteins [33]. However, this approach ignores the 
many protein isoforms generated by protein modifications or variations in transcriptional 
control. In addition, the limiting factor for analytical microarrays is the availability of 
capture molecules with sufficient specificity and affinity- for example, an antibody array 
may recognize multiple variants of the same protein, masking potentially important 
changes at the level of protein modification. Nevertheless, microarray technology offers 
the ability to assay biological function such as ligand binding properties, phosphorylation 
or protein-protein interactions and promises, amongst other things, to form the basis of an 
important clinical diagnostic tool. Zhu et al. have cloned as GST fusions ~5800 ORF’s 
from the yeast S. cerevisiae to produce a functional microarray [54], and antibody 
microarrays are now commercially available from BioChip Technologies [117]. The 
ability to produce unique proteins arrays for any individual, as provided by the ChIP 
[103], is a particularly powerful development which will assuredly have far-reaching 
applications in the future. 
A major area of interest in proteomics is the post-translational modification of 
proteins. Recently, Proteome Systems [103] launched GlycosuiteTM, a new database of 
glycan structures and protein modifications which interfaces directly with BioinformatIQ 
[55, 56]. This software has already been employed in the proteomic identification of 
glycoprotein targets with a view to developing new therapeutics to combat lung disease 
in patients suffering from cystic fibrosis [41]. Glycosuite has also been used to examine 
glycan structures present on human plasma glycoproteins [32, 57]. The ability to analyze 
glycosylation modifications on proteins provides a powerful addition to the integrated 
package of proteomics research tools. 
Systems biology relies on the quality of the databases it exploits, and informatics 
packages such as BioinformatIQ, designed to handle large and diverse datasets and 
directly integrate them with genomics and bioinformatics databases, are a major step in 
the right direction. Currently, our ability to collect data far outweighs our ability to 
analyze it in a meaningful way. To provide further insights into the functional 
organization of complex biological systems, integration of centralized proteomics 
databases with validation data, activity profiles, interaction maps and protein 
modifications will become standard. It has been proposed that a score might be assigned 
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to proteins in such a database, as a measure of confidence for any protein interactions 
observed [12]. Of course, the complexity and context-dependent nature of each 
component in a biological network make this a daunting task which will be some time 
away. An interesting proposition is the development of modeling algorithms for the 
integration of such information [58]. These might be used to predict interacting 
components of pathways, which may not be expected by typical biochemical techniques 
or knowledge-based approaches. Such an integrated genomics and proteomics approach 
has been applied to the galactose metabolic network in yeast [59]. By assimilating data 
using similar algorithms, it should become possible to produce computational models for 
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• proteomics research generates very large and diverse datasets, which require a 
coordinated approach to data collection and analysis 
• high throughput proteomics requires integration for storing, manipulating and 
mining large amounts of data, and automation for consistent sample handling on a 
large scale 
• the application of new, integrated start-to-finish automated proteomics platforms 
such as ProteomIQ simplifies proteomic analyses and facilitates rapid and 
efficient data collection, analysis and archiving 
• increased detection sensitivity, new adjuncts to 2DE technology and more 
integrated informatics approaches will continue to drive proteomics research and 
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TABLE 1. CONSUMABLES REQUIRED IN THE PROTEOMIQ PLATFORM. 
PROCESS / CONSUMABLES DESCRIPTION/COMMENTS 
 
SAMPLE PREPARATION  
ProteoPrep Extraction Kits 
Includes detergents, solubilizing solutions, 
reducing and alkylating reagents. Specific 
kits for general proteins, membrane 
proteins or universal extraction 
Montage Albumin Deplete Kit Rapid removal of albumin from serum and plasma 
 
PRE-FRACTIONATION  
ProteomIQ MCE Kit 
Includes sample solubilising solutions for 
either general or low solubility proteins, 
and immobilized pH membranes used for 
preparative isoelectric fractionation 
 
ISOELECTRIC FOCUSING  
Immobilized pH gradient strips 
OrangeG tracking dye 
IPG wicks 
Pre-cast, broad and narrow range IPG strips 
and other consumables for IEF 
Sample rehydration/equilibration trays 
IEF tray Disposable or reusable 
 
SDS-PAGE  
ProteomIQ GelChip Tris-acetate 6-15% gradient small format (10x15cm) gels for use in ElectrophoretIQ 
ProteomIQ running buffer, tris/tricine/SDS 
Equilibration buffer 
Standard buffers for gel running and IEF 
strip equilibration 
 
WESTERN BLOTTING  
ProteomIQ Blotting kit Reagents, blotting paper and PVDF membrane for western blotting 
 
PROTEIN STAIN  
ProteomIQ Blue Gel Stain kit Colloidal Coomassie gel stain, MS-compatible 
ProteomIQ Blot Stain Kit, Direct Blue 71 Protein stain for use with PVDF membrane 
 
PROTEIN PROCESSING  
ProteomIQ Xcise In-Gel Digest Kit 
Contains reagents, MTP plates, ZipTips™ 
and plastic solution trays designed for use 
in Xcise for spot cutting and peptide 






Fig 1. A typical proteomics workflow on the ProteomIQ platform. Samples are 
prepared and pre-fractionated if desired, and the workflow entered into the LIMS 
component of BioinformatIQ (right). Proteins are then separated by 2DE and image 
analysis of the stained gels identifies protein spots of interest. These proteins are excised 
from the gel, digested and the peptides identified by MS analysis. At each step, 
information concerning the experiment is uploaded into BioinformatIQ, and appropriate 
information for the next step is downloaded (arrows) into robotic equipment for 
generation of automated protocols. 
 
Fig 2. Prefractionation of proteins into discrete pH ranges increases resolution in 
2DE. (a) the MCE device used for pre-fractionation of proteins. The multi-chamber 
design allows a sample to be fractionated into up to five pH increments, depending on 
requirements. (b) Proteins isolated from the gram positive bacterium Bacillus subtilis 
were fractionated using an MCE device and the pH 6.5-11 fraction arrayed by 2DE. First 
dimension focusing was in precast IPG strips covering the pH 3-10 range, and second 
dimension SDS-PAGE was in 6-15% gradient GelChipsTM. Proteins were visualized by 
staining with silver. 
 
Fig 3. Hardware components of the ProteomIQ platform for 2DE. (a) the IsoelectrIQ, 
displayed with one MCE and two different sizes of IEF modules on board; (b) the 
ElectrophoretIQ, displayed with two SDS-PAGE modules on board; (c) individual 
modules for use in the IsoelectrIQ or ElectrophoretIQ. From left; IEF module, SDS-
PAGE module, western blotting module. 
 
Fig 4. The Xcise liquid handling robot and user interface. Gels are placed into the 
enclosed gel platform, and the processes of spot cutting, gel destaining, protein digestion, 
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peptide purification and deposition onto a MALDI target plate are carried out 
automatically. 
 
Fig 5. The ChIP chemical inkjet printer. (a) The ChIP. (b) A stained blot loaded under 
the print head of the ChIP. (c) Reagents are dispensed from a piezoelectric microjet over 
selected bands (represented as white lanes over the magnified bands of interest) onto the 
membrane surface. Primary and secondary antibody, blocking and washing solutions are 
all dispensed in this manner and the blot developed. (d) Comparison of conventional 
blotting versus ChIP nanowestern blotting. Cytoskeletal supernatant samples from mast 
cells were probed using antibodies as shown. Multiple experiments may be performed on 
a single blot or a single protein spot in this manner. From left; a stained protein blot from 
1D SDS-PAGE gel; 3 conventional replicate western blots probed with anti-myosin, anti-
vimentin or anti-actin antibodies; a single replicate western blot probed with all three 
antibodies using the ChIP. 
 
Fig 6. The BioinformatIQ web interface. The tree structure of the BioinformatIQ user 
interface, showing (a) organization of a current project, and (b) details of an experiment 
in progress. 
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